

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Galileo Pharmaceuticals, Inc.	03/01/2007
RECEIVING PARTY DATA	
Name:	Edison Pharmaceuticals, Inc.
Street Address:	5941 Optical Court
Internal Address:	Suite 228
City:	San Jose
State/Country:	CALIFORNIA
Postal Code:	94304
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7078541
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	650 813-5715
Email:	drovetti@mofo.com
Correspondent Name:	Robert K. Cerpa
Address Line 1:	Morrison & Foerster
Address Line 2:	755 Page Mill Road
Address Line 4:	Palo Alto, CALIFORNIA 94304-1018
ATTORNEY DOCKET NUMBER:	526302001220
NAME OF SUBMITTER:	Robert K. Cerpa
Total Attachments: 6 source=Document#page1.tif source=Document#page2.tif	

CH 7078541 \$40.00

500277327

PATENT
REEL: 019287 FRAME: 0696

source=Document#page3.tif
source=Document#page4.tif
source=Document#page5.tif
source=Document#page6.tif

now

ASSIGNMENT

WHEREAS, GALILEO PHARMACEUTICALS, INC., a California corporation, (hereinafter referred to as "Assignor") owns all right, title and interest in and to certain patents and patent applications identified in Exhibit 1 attached hereto, and incorporated herein by reference; and

WHEREAS, EDISON PHARMACEUTICALS, INC., a Delaware corporation (hereinafter referred to as "Assignee"), is desirous of acquiring all rights, title, and interest in and under the patents identified in Exhibit 1 to this Assignment.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors and assigns its full and exclusive right, title and interest to those patents and patent applications (including provisional patent applications and any continuations, continuations-in-part applications, and any divisionals, provisionals or substitute applications with respect to any such patent applications), any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental patent certificate) of any such patent, and any confirmation patent, registration patent, patent of addition, or inventor's certificate based on or directed to the subject matter claimed in any such patent, and all patents and patent applications anywhere in the world that at any time, directly or indirectly, claim priority from, support a claim of priority of or contain substantially identical disclosure as any of the foregoing), identified as such in Exhibit 1 attached hereto, together with all causes of action and enforcement rights for such patent applications and patents including all rights to pursue damages, injunctive relief and other remedies for past and future infringement thereof.

ASSIGNOR HEREBY AUTHORIZES Assignee and its attorney of record to insert on this assignment document, including Exhibit 1, any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office and/or any foreign patent office for recordation of this document.

IN WITNESS WHEREOF, Assignor has caused one of its authorized representatives to hereunder set his hand on the date shown below and Assignee has caused one of its officers to hereunder set his hand on the date shown below to signify its acceptance of this Assignment.

GALILEO PHARMACEUTICALS, INC.

By: [Signature]

Name: Lloyd Kumimoto

Title: Chief Executive Officer

Date: 03/01, 2007

STATE OF CALIFORNIA)
COUNTY OF YOLO) SS:

On this 01 day of MARCH 2007 before me, a Notary Public in and for said county, appeared Lloyd Kumimoto who is personally known to me to be the same person whose name is subscribed to the foregoing assignment document, and acknowledged that he/she signed and delivered the document as his/her free and voluntary act for the uses and purposes therein set forth.

[Signature]
Notary Public
(SEAL)



My Commission Expires: Aug. 24, 2010

Accepted

EDISON PHARMACEUTICALS, INC.

By: _____

Name:

Title:

Date: _____, 2007

new

ASSIGNMENT

WHEREAS, GALILEO PHARMACEUTICALS, INC., a California corporation, (hereinafter referred to as "Assignor") owns all right, title and interest in and to certain patents and patent applications identified in Exhibit 1 attached hereto, and incorporated herein by reference; and

WHEREAS, EDISON PHARMACEUTICALS, INC., a Delaware corporation (hereinafter referred to as "Assignee"), is desirous of acquiring all rights, title, and interest in and under the patents identified in Exhibit 1 to this Assignment.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors and assigns its full and exclusive right, title and interest to those patents and patent applications (including provisional patent applications and any continuations, continuations-in-part applications, and any divisionals, provisionals or substitute applications with respect to any such patent applications), any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental patent certificate) of any such patent, and any confirmation patent, registration patent, patent of addition, or inventor's certificate based on or directed to the subject matter claimed in any such patent, and all patents and patent applications anywhere in the world that at any time, directly or indirectly, claim priority from, support a claim of priority of or contain substantially identical disclosure as any of the foregoing), identified as such in Exhibit 1 attached hereto, together with all causes of action and enforcement rights for such patent applications and patents including all rights to pursue damages, injunctive relief and other remedies for past and future infringement thereof.

ASSIGNOR HEREBY AUTHORIZES Assignee and its attorney of record to insert on this assignment document, including Exhibit 1, any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office and/or any foreign patent office for recordation of this document.

IN WITNESS WHEREOF, Assignor has caused one of its authorized representatives to hereunder set his hand on the date shown below and Assignee has caused one of its officers to hereunder set his hand on the date shown below to signify its acceptance of this Assignment.

GALILEO PHARMACEUTICALS, INC.

By: _____
Name: Lloyd Kumamoto
Title: Chief Executive Officer
Date: _____, 2007

STATE OF _____ }
COUNTY OF _____ } SS:

On this _____ day of _____, 2007 before me, a Notary Public in and for said county, appeared _____, who is personally known to me to be the same person whose name is subscribed to the foregoing assignment document, and acknowledged that he/she signed and delivered the document as his/her free and voluntary act for the uses and purposes therein set forth.

Notary Public
{SEAL}
My Commission Expires: _____

Accepted

EDISON PHARMACEUTICALS, INC.


By:  _____
Name: Mark
Title: CEO
Date: August 12, 2007

Exhibit 1

No.	Gal. Ref. No.	Docket ID	Short Title	Country	Status	Publication No./ Grant No.	Publication Date/ Grant Date
1.	0101-UTL	310473-1050	Method and Composition for Inhibiting Cellular Irreversible Changes Due to Stress	U.S.	Granted	5,801,159	9/1/1998
2.	102-UTL	310473-1100	Assay System for anti-Stress Agents	U.S.	Granted	6,232,060	5/15/2001
3.	0109-UTL	310473-1250	Methods for the Prevention and Treatment of Cerebral Ischemia Using Non-Alpha Tocopherols	U.S.	Granted	7,034,054	4/25/2006
4.	110-UTL	310473-1300	Process for Solid Supported Synthesis of Pyruvate Derived Compounds	U.S.	Granted	6,608,196	8/19/2003
5.	0118-CA	310473-1852	Furanone Derivatives	Canada	Pending	2474871	1/30/2003
6.	0118-JP	310473-1853	Furanone Derivatives	Japan	Pending	2003-564026	1/30/2003
7.	0118-MX	310473-1854	Furanone Derivatives	Mexico	Pending	PA/a/2004/007292	1/30/2003
8.	0118-NZ	310473-1855	Furanone Derivatives	New Zealand	Granted	534305	1/30/2003
9.	0118-EP	310473-1856	Furanones Derivatives	EPO	Pending	03705988.8	1/30/2003
10.	0119-CA	310473-1902	Cytoprotective Benzofuran Derivatives	Canada	Pending	2474974	2/6/2003
11.	0119-JP	310473-1903	Cytoprotective Benzofuran Derivatives	Japan	Pending	2003-565991	2/6/2003

No.	Gal. Ref. No.	Docket ID	Short Title	Country	Status	Publication No./ Grant No.	Publication Date/ Grant Date
12.	0119-MX	310473-1904	Cytoprotective Benzofuran Derivatives	Mexico	Pending	PA/a/2004/007550	2/6/2003
13.	0119-US	310473-1907	Cytoprotective Benzofuran Derivatives	U.S.	Granted	6,653,346	11/25/2003
14.	0119-US-02	310473-3350	Benzofuran Derivatives	U.S.	Granted	7,078,541	7/18/2006
15.	0119-CA02	310473-3352	Benzofuran Derivatives	Canada	Not yet filed	PCT/US2004/030366	9/15/2004
16.	0135-UTL2	310473-4050	Chroman Derivatives	U.S.	Pending	2005-0065150	3/24/2005
17.	0135-CA02	310473-4052	Chroman Derivatives	Canada	Not yet filed	PCT/US2004/030009	Not yet filed
18.	0135-UTL3	310473-4100	Treatment of Mitochondrial Diseases	U.S.	Pending	2005-0065099	3/24/2005
19.	0135-CA03	310473-4102	Treatment of Mitochondrial Diseases	Canada	Not yet filed	PCT/US2004/030008	Not yet filed
20.	0135-UTL1	310473-4150	7,8-Bicycloalkyl-Chroman Derivatives	U.S.	Pending	2005-0065149	3/24/2005
21.	035-CA01	310473-4152	7,8-Bicycloalkyl-Chroman Derivatives	Canada	Not yet filed	PCT/US2004/029852	Not yet filed